Clinical Trials on Influenza A Virus, H7N9 Subtype

Total 5016 results

Novavax
Instituto Mexicano del Seguro Social

Completed

Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine

Seasonal Influenza

Mexico
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects

Seasonal Influenza

Italy
University of Pennsylvania
Yale University; Stanford University; Harvard University

Completed

The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates

Seasonal Influenza

United States
Hadassah Medical Organization

Unknown

Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation

H1N1 Influenza

Israel
Novartis
Novartis Vaccines

Completed

Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

Influenza Infection

Switzerland
Centers for Disease Control, Taiwan
Public Health Bureau,Taoyan County Governmnet, Taiwan; Education Department...

Completed

Evaluation of a School-based Influenza Vaccination Program

Influenza | Influenza Vaccines

Taiwan
HaEmek Medical Center, Israel

Completed

The Effectiveness of Influenza Vaccine Among Health Care Workers in a Hospital Setting.

Influenza Vaccines

Israel
Assistance Publique - Hôpitaux de Paris

Terminated

Influenza Vaccination of Nursing Home Workers.

Influenza Disease

France
Sanofi Pasteur, a Sanofi Company

Recruiting

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Influenza Immunization

United States, Puerto Rico
Changchun BCHT Biotechnology Co.
Hu Bei province Center for Disease control and prevention; The Inner Mongolia...

Recruiting

Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine

Influenza Prevention

China
Tan Tock Seng Hospital
Sanofi; A*Star; World Health Organization Collaborating Centre for Reference...

Recruiting

Immunogenicity Trial of 3 Influenza Vaccines

Influenza Vaccination

Singapore
University of Pennsylvania

Recruiting

Study of Immune Responses to Influenza Vaccination

Influenza Vaccination

United States
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Influenza Immunization

Puerto Rico, United States
National Institute of Allergy and Infectious Diseases...

Completed

Flublok or Fluzone With Advax-CpG55.2 or AF03

Influenza | Influenza Immunisation

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

Influenza Immunization

United States, Denmark, Poland, Spain, Czechia
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

Seasonal Influenza

United States
Novartis Vaccines

Completed

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012

Seasonal Influenza

Italy
Copenhagen Studies on Asthma in Childhood
Novartis

Completed

H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza A H1N1v Vaccination in Pregnant Women

H1N1v Influenza

Denmark
BlueWillow Biologics
National Institute of Allergy and Infectious Diseases (NIAID); University of...

Active, not recruiting

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults (IN-NE-rH5)

Influenza, Pandemic

United States
AB Biotics, SA

Completed

Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination (FLUVAC21)

Influenza Vaccine

Spain
National Institute of Allergy and Infectious Diseases...

Completed

Development of Childhood Anti-Influenza Immunity

Influenza | Influenza Immunisation

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects

Seasonal Influenza

Germany
GlaxoSmithKline

Terminated

Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children

Influenza | Influenza Vaccines

Spain
GlaxoSmithKline

Completed

Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population

Influenza | Influenza Vaccines

Germany
GlaxoSmithKline

Completed

A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk

Influenza Vaccines

Canada
PharmaJet, Inc.

Completed

Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe

Influenza Prophylaxis

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects

Prophylaxis: Influenza

United States
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

Seasonal Influenza

China
The University of Texas Health Science Center,...
Gilstrap, Larry C, M.D.

Completed

Opting In vs Opting Out

Influenza Vaccination

United States
Butantan Institute

Completed

Active Surveillance for Adverse Events Following Immunization With the Influenza Vaccine Produced at Butantan Institute (FLU-05-IB)

Influenza Vaccines

Brazil
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Dominican Republic, Belgium, Germany
University of Pennsylvania
Yale University; Stanford University; Harvard University

Completed

The Effect of Time-Slot Scheduling on Flu Vaccination Rates

Seasonal Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009

Interpandemic Influenza

Italy
Novartis
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.

Human Influenza

Brazil
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Adults

Influenza | Pandemic Influenza

Austria, Germany
Butantan Institute
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients

Human Influenza

Brazil
University of Alberta

Completed

Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients

Influenza Vaccine

Canada
Centers for Disease Control and Prevention
Universidad del Valle, Guatemala; Hospital Nacional San Juan de Dios de Santa... and other collaborators

Terminated

Panama and El Salvador Children's Oseltamivir Study (PECOS)

Influenza | Human Influenza

Panama, El Salvador
Novartis Vaccines

Completed

Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

Human Influenza

Belgium
Novavax
Department of Health and Human Services

Completed

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

Influenza (Pandemic)

United States
Novavax

Completed

Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)

Seasonal Influenza

United States
Hualan Biological Engineering, Inc.

Completed

Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine

Human Influenza

China
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza (PIPET A)

Pandemic Influenza

Australia
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects

Influenza Disease

Italy
Assistance Publique - Hôpitaux de Paris
GlaxoSmithKline; Hoffmann-La Roche

Terminated

Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir (BIVIR)

Gastric Influenza

France
Meso Scale Diagnostics, LLC.
Centers for Disease Control and Prevention

Terminated

Clinical Validation of the Point-of-Care MSD Influenza Test

Influenza Human

United States
Novartis Vaccines

Completed

Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers

Seasonal Influenza

Vietnam

3

Subscribe